Bank of America analysts have projected a potentially sharp acceleration in earnings growth for UBS Group AG , positioning ...
StockStory.org on MSN
Why Corcept (CORT) Stock Is Down Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.2% in the afternoon session after investment bank UBS initiated coverage of the company with a Neutral rating.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback